TECENTRIQ® (Atezolizumab)

The FDA on May 18, 2016 granted accelerated approval to TECENTRIQ® injection for the treatment of patients with locally advanced or metastatic Urothelial carcinoma, who have disease progression during or following Platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with Platinum-containing chemotherapy. TECENTRIQ® is a Programmed Death-ligand 1 (PD-L1) blocking antibody and is a product of Genentech, Inc.

OPDIVO® (Nivolumab)

The FDA on May 17, 2016 granted accelerated approval to OPDIVO® for the treatment of patients with classical Hodgkin Lymphoma (cHL) that has relapsed or progressed after autologous Hematopoietic Stem Cell Transplantation (HSCT) and post-transplantation ADCETRIS® (Brentuximab vedotin). OPDIVO® is marketed by Bristol-Myers Squibb company

LENVIMA® (Lenvatinib)

The FDA on May 13, 2016 approved LENVIMA® capsules in combination with AFINITOR® (Everolimus), for the treatment of advanced Renal Cell Carcinoma following one prior anti-angiogenic therapy. LENVIMA® was first approved in 2015 for the treatment of locally recurrent or metastatic, progressive, RadioActive Iodine-refractory Differentiated Thyroid Cancer. LENVIMA® is a product of Eisai, Inc.

VENCLEXTA® (Venetoclax)

The FDA on April 11, 2016 approved VENCLEXTA® for the treatment of patients with Chronic Lymphocytic Leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. VENCLEXTA® tablets are marketed by AbbVie, Inc. and Genentech USA, Inc.

DEFITELIO® (Defibrotide Sodium)

The FDA on March 30, 2016 approved DEFITELIO® for the treatment of adult and pediatric patients with hepatic Veno-Occlusive Disease (VOD), also known as sinusoidal obstructive syndrome, with renal or pulmonary dysfunction, following Hematopoietic Stem Cell Transplantation (HSCT). DEFITELIO® is a product of Jazz Pharmaceuticals, Inc.

XALKORI® (Crizotinib)

The FDA on March 11, 2016 approved XALKORI® capsules for the treatment of patients with metastatic Non Small Cell Lung Cancer (NSCLC) whose tumors are ROS1-positive. XALKORI® is a product of Pfizer, Inc.

AFINITOR® (Everolimus)

The FDA on February 26, 2016 approved AFINITOR® for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease. AFINITOR® is a product of Novartis Pharmaceuticals Corporation.

GAZYVA® (Obinutuzumab)

The FDA on February 26, 2016 approved GAZYVA® for use in combination with Bendamustine followed by GAZYVA® monotherapy for the treatment of patients with Follicular Lymphoma (FL) who relapsed after, or are refractory to, a RITUXAN® (Rituximab) containing regimen. GAZYVA® was previously approved for use in combination with Chlorambucil for the treatment of patients with previously untreated Chronic Lymphocytic Leukemia. GAZYVA® injection is a product of Genentech, Inc.

IBRANCE® (Palbociclib)

The FDA on February 19, 2016 approved IBRANCE® in combination with FASLODEX® (Fulvestrant) for the treatment of women with hormone receptor (HR) positive, Human Epidermal growth factor Receptor 2 (HER2)-negative advanced or metastatic breast cancer, with disease progression following endocrine therapy. IBRANCE® capsules are a product of Pfizer, Inc.